Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Chemotherapy. Hormone. University Medical Center Groningen, University of Groningen, Groningen, Netherlands



Survival: 27.0 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
Hormone
   
Drugs:
Country: Netherlands
   
City/State/Province: Groningen
   
Hospital: University Medical Center Groningen, University of Groningen
   
Journal: Link
   
Date: 7/2011

Description:
Patients:
This phase 2 study involved 20 peripheral T-cell lymphoma patients. The median patient age was 50 years and 11 were male.

Treatment:
Patients were treated with the chemotherapy agents cyclophosphamide, doxorubicin, and vincristine, the hormone prednisone, and the biologic therapy agent alemtuzumab (an antibody against the CD52 protein that helps the immune system attack cancer cells).

Toxicities:
Treatment-related deaths due to infection were reported. Grade 4 allergic reactions and lung problems were also reported.

Results:
The median overall survival was 27 months.

Support:
This study was supported by Bayer Schering Pharma (makers of alemtuzumab) and Genzyme.

Correspondence: Dr. H. C. Kluin-Nelemans; email: j.c.kluin@int.umcg.nl

E-mail to a Friend Email Physician More Information